Alnylam was among my first investments, and I've learned a lot by following the company and holding the stock these 10+ years. Among them, beware of believing the most bullish forecasts, but be open to the possibility of transformative science. ALNY hasn't been my most profitable investment, but it's still the one I most enjoy following. It's frankly amazing that they're now talking about making drugs that can be administered annually, and I'm looking forward to seeing how the CNS platform performs, as well as any M&A the company might undertake.
I'm a little puzzled why the stock has been so strong lately in a weak biotech market, but I'll take it!